The pooled OR from seven studies comprising 289 ccRCC and 144 non-ccRCC patients suggested that p16INK4A promoter methylation was not significantly associated with tumor histology in RCC (OR = 0.54, 95% CI = 0.29-1.00, P = 0.051) (Table 4). Here, CDKN2A is linked to neoplasm.